Mori S, El-Baki H, Mullen C A
Department of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Bone Marrow Transplant. 2003 May;31(10):865-75. doi: 10.1038/sj.bmt.1704021.
In major histocompatibility complex (MHC)-matched allogeneic hematopoietic stem cell transplantation (HSCT), donor responses are directed against multiple host minor histocompatibility antigens (mHAgs), producing graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) effects. We studied MHC-matched, mHAg-mismatched C3H.SW>C57BL/6 HSCT in which three mHAg are molecularly defined (B6dom1, H3, H13) to determine if there is a hierarchy of immunodominance among the mHAgs and to learn the contribution of each to GVHD. We found that B6dom1 was the immunodominant mHAg. B6dom1 did not block responses to the subdominant mHAgs H3 and H13. The mechanism of immunodominance was not mHAg avidity or affinity for class I. B6dom1 elicited a broader variety of Vbeta clonotypes than either H3 or H13. Severe GVHD could occur in the absence of a strong B6dom1 response. Alloreactivity to isolated B6dom1, H3 or H13 differences did not produce severe GVHD. We concluded that immunodominance is explained by both mHAg density on host cells and the repertoire of donor T cells capable of responding to the mHAgs. Clinically significant GVHD requires donor responses to multiple mHAgs. Modulation of responses to a single immunodominant mHAg is insufficient for the prevention of GVHD, while immunotherapies directed against isolated mHAgs may not provoke severe GVHD.
在主要组织相容性复合体(MHC)匹配的同种异体造血干细胞移植(HSCT)中,供体反应针对多种宿主次要组织相容性抗原(mHAg),产生移植物抗宿主病(GVHD)和移植物抗肿瘤(GVT)效应。我们研究了MHC匹配、mHAg不匹配的C3H.SW>C57BL/6 HSCT,其中三种mHAg在分子水平上已明确(B6dom1、H3、H13),以确定mHAg之间是否存在免疫显性等级,并了解每种mHAg对GVHD的贡献。我们发现B6dom1是免疫显性mHAg。B6dom1并未阻断对次要mHAg H3和H13的反应。免疫显性机制并非mHAg对I类分子的亲和力或亲合力。B6dom1诱导的Vβ克隆型比H3或H13更多样化。在没有强烈的B6dom1反应时也可能发生严重GVHD。对分离出的B6dom1、H3或H13差异的同种异体反应性不会产生严重GVHD。我们得出结论,免疫显性可由宿主细胞上mHAg的密度以及能够对mHAg作出反应的供体T细胞库来解释。具有临床意义的GVHD需要供体对多种mHAg作出反应。调节对单一免疫显性mHAg的反应不足以预防GVHD,而针对分离出的mHAg的免疫疗法可能不会引发严重GVHD。